Johnson & Johnson Innovation closed a transaction of Series A funding as the co-lead investor in TECLens, an early-stage startup focusing on a non-incisional procedure for refractive correction.
TECLens aims to develop a noninvasive treatment to reshape the cornea without laser ablation by utilizing quantitative corneal cross-linking technology and the company’s CXLens device, according to information on Johnson & Johnson’s website.
“J&J is excited to invest in this early ophthalmic innovation which complements our existing expertise in contact lens and refractive